Navigation Links
EntreMed Receives New Patent for 2-Methoxyestradiol Analogs
Date:6/11/2008

atent covering the issued claims is owned exclusively by EntreMed.

James S. Burns, EntreMed President & Chief Executive Officer, commented, "This patent is the result of an extensive internal program to identify novel compounds based on our expertise in angiogenesis, cell cycle regulation and cell signaling. This patent further strengthens our intellectual property position in next generation antimitotic and antiangiogenic drugs for the treatment of cancer. ENMD-1198, a lead compound resulting from our analog program, is currently in a Phase 1 study in advanced cancers. We anticipate completion of the study in the second half of 2008. Additional studies, including an expanded Phase 1 or Phase 2 trial, are planned for later this year."

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business perfo
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. EntreMed to Present at The New York Society of Security Analysts Industry Conference
7. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
8. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
9. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
10. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
11. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
(Date:7/10/2014)... to bump up their grade point averages during college, ... a library or study hall, but in a gym. ... who were members of the recreational sports and fitness ... years had higher GPAs than those who weren,t. ... stayed in school longer. An increase of 3.5 percent ...
(Date:7/10/2014)... review identifying the clinical indicators most strongly associated with ... of developing evidence-based guidelines for concussion diagnosis, prognosis, and ... Neurosurgery , official journal of the ... published by Lippincott Williams & Wilkins , a ... , Based on analysis of the best available research ...
(Date:7/10/2014)... that are just as tempting as full-fat equivalents ... fresh insights into how proteins can replace fats ... Funded by the Engineering and Physical Sciences Research ... the University of Edinburgh has produced modified proteins ... closely mimic the behaviour of fats during food ...
(Date:7/9/2014)... episodes of low back pain are not linked to ... direction and precipitation. Findings published in Arthritis Care ... of Rheumatology (ACR), indicate that the risk of low ... wind gusts, but was not clinically significant. , ... experiences low back pain at some point in their ...
(Date:7/9/2014)... active in almost all types of cancer sends the ... help fuel a tumour,s uncontrolled growth, new research suggests. ... identified a molecular trigger responsible for ratcheting up activity ... that makes the building blocks cancer cells need to ... pathway, called SREBP, controls the flow of messages to ...
Breaking Medicine News(10 mins):Health News:Want a higher GPA in college? Join a gym 2Health News:What's a concussion? Review identifies four evidence-based indicators 2Health News:What's a concussion? Review identifies four evidence-based indicators 3Health News:Great tasting low-fat cheeses and cakes could soon be on the menu 2Health News:Low back pain? Don't blame the weather 2Health News:Signal may send cancer's cellular factories into overdrive 2
... and lack of proper sleep could be threatening thousands ... warns Heart and Stroke Foundation researcher Dr. Brian McCrindle, ... in Toronto. "Sleep disorders in kids are on ... other increasing cardiovascular risk factors such as overweight and ...
... 25, 2010 Young children who consume substantial amounts ... with fluoridated water or by swallowing fluoride toothpaste have ... to research published in the October issue of The ... supported by the National Institute of Dental and Craniofacial ...
... fear some of it unjustified are common among ... as MRSA, according to the results of a small study ... timely, detailed and simple information, the researchers add. ... Pediatrics , underscore the need for healthcare staff to do ...
... Reporter , MONDAY, Oct. 25 (HealthDay News) -- Why is ... the next day one person ends up feeling more tired ... in their genes, a new study suggests. Researchers at ... individuals who test positive for a common gene variant are ...
... Randy Dotinga HealthDay Reporter , MONDAY, Oct. 25 ... -- to be honest about their drug use, a new ... extent of drug use, but this new research finds that ... for drugs or they,re told the results will be confidential. ...
... treated with a combination of hormone therapy and radiation have ... do not receive radiation, according to interim results of the ... session, November 1, 2010, at the 52nd Annual Meeting of ... 1995 to 2005, 1,205 men with high-risk prostate cancer in ...
Cached Medicine News:Health News:Cardiac wakeup call for Canadian kids 2Health News:Cardiac wakeup call for Canadian kids 3Health News:Substantial consumption of fluoride increases chance of mild fluorosis 2Health News:Knowledge gaps, fears common among parents of children with drug-resistant bacteria 2Health News:Knowledge gaps, fears common among parents of children with drug-resistant bacteria 3Health News:How You Handle Lack of Sleep May Be in Your Genes 2Health News:How You Handle Lack of Sleep May Be in Your Genes 3Health News:Teens, Parents Often Lie About Illicit Drug Use 2Health News:Adding radiation to hormone therapy for prostate cancer treatment will increase survival chances 2
Fluar objectives have been designed especially for qualitative and quantitative analyses of ion movements and for particularly critical fluorescence methods (e.g. chromosome studies in human and cyto...
... high-power, apochromatically corrected objectives ... the most exacting demands ... are suitable for visual ... 25 mm and feature ...
... transmission rate in the ultraviolet down to ... fluor-3; these objectives have,improved signal to noise ... Numerical Apertures for significantly sharper and brighter ... and a 2mm working distance to allow ...
... distances with high Numerical Apertures, these objectives ... aberrations throughout the visible spectrum from violet ... the entire 25mm field of view. They ... reproduction, plus resolving power at the theoretical ...
Medicine Products: